Oncology Letters · 2021 · 14 citations · 28 references
MedicineOncologyPathologyCarcinogenesisMolecular OncologyNeoplasiaBiliary Tract CancerCancer Molecular PathologyChromatinHepatobiliary CancerLiver CancerTumor ClassificationChromatin RemodelingIntrahepatic Cholangiocarcinoma SurgeryLoss Of Protein FunctionMicroarray AnalysisSurvival RatesTissue Microarray AnalysisTumor Suppression MechanismsTumor Suppression Pathways
Cholangiocarcinoma (CCA) is an aggressive malignancy with a 5-year-survival rate of <10%, mainly due to diagnosis in advanced stages and limited therapeutic options in case of progressive disease. Recently, evidence has indicated that alterations in the SWI/SNF-complex (SWI/SNF) may have an important role in the tumorigenesis of CCA. SWI/SNF-related chromatin remodeling has been reported to be crucial for differentiation and tumor suppression, and loss-of-function mutations of SWI/SNF are present in 20% of human malignancies; however, at present, little is known about its relevance in CCA. In the present study, a cohort of 52 patients with the diagnosis of primary CCA was retrospectively collected. All patients underwent surgery with curative intent. Tissue microarray analysis was performed on each tumor for immunohistochemical loss-of-protein analysis of the SWI/SNF core subunits ARID1A, INI-1, BRG1, PBRM-1 and BRM, corresponding to the following CCA subtypes: Extrahepatic CCA (ECCA), small duct or large duct intrahepatic CCA (ICCA). Kaplan-Meier analysis was used to determine survival distribution and survival differences were evaluated by log-rank test. In total, 14 of 52 patients (~35%) exhibited protein-loss of any tested SWI/SNF core subunit. Notably, 17% of patients exhibited a loss of ARID1a; this was the protein loss with the highest frequency. Patients with small and large duct ICCA with protein-loss of any tested SWI/SNF subunit exhibited significantly worse survival compared with the wild-type cohort with proficient protein expression (P=0.013 and P=0.002), whereas no significant survival difference was detected for patients with ECCA. SWI/SNF and its core subunits may be considered promising predictive and therapeutic targets, and require further investigation in patients with CCA.
28
The 2019 WHO classification of tumours of the digestive system
Irıs D. Nagtegaal, Robert D. Odze, David S. Klimstra et al. · Histopathology · 2019 · 4.1K citations · Full text
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater, Peter R. Galle, Shahid A. Khan et al. · Journal of Hepatology · 2014 · 1.5K citations
Medicine, Oncology, Pathobiology +11
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu, Fengyun Su, Shanker Kalyana‐Sundaram et al. · Cancer Discovery · 2013 · 738 citations · Full text
Life Sciences, Genetics, Oncology +12